Allogeneic Blood Stem Cell Transplantation and Adoptive Immunotherapy for Hodgkin's Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

July 31, 2005

Primary Completion Date

August 31, 2016

Study Completion Date

August 31, 2016

Conditions
Hodgkin's Disease
Interventions
DRUG

Gemcitabine

800 mg/m\^2 IV over 30 minutes on Day -7 (1 day)

DRUG

Fludarabine

33 mg/m\^2 IV over 30 minutes Day -5 to Day -2 (4 days)

DRUG

Melphalan

70 mg/m\^2 IV over 30 minutes on Day -3 to Day -2 (2 days)

DRUG

Antithymocyte Globulin

"2 mg/kg IV on Day -4 and Day -3 (2 days) before stem cell transplantation.~If receiving transplant from matched unrelated donor (not a blood relative), a mismatched related donor (a blood relative, but not a full match), or receiving a cord blood transplant."

PROCEDURE

Allogeneic Stem Cell Infusion

Infusion of stem cells on Day 0.

DRUG

Tacrolimus

0.03 mg/kg beginning Day -2 by vein over 24 hours; when tolerable change to pill form given once daily for 3-4 months.

DRUG

Filgrastim (G-CSF)

Starting 1 week after transplant (Day +7) given as injection under the skin once daily until blood cell levels return to normal.

DRUG

Methotrexate

5 mg/m2 by vein on Days +1, +3, +6, and +11 to decrease risk of GVHD.

Trial Locations (1)

77030

University of Texas MD Anderson Cancer Center, Houston

All Listed Sponsors
lead

M.D. Anderson Cancer Center

OTHER

NCT00385788 - Allogeneic Blood Stem Cell Transplantation and Adoptive Immunotherapy for Hodgkin's Disease | Biotech Hunter | Biotech Hunter